You are here: Industry Insights > Market News > NATCO launches Rivaroxaban¸ anticoagulant medication in India

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

SG-DJ10 Capsule and Tablet Sample Checkweigher

NADP+

NMN

Ceritinib (LDK378) CAS:1032900-25-6

SG-JN10 0.1mg Tablet Capsule Check Weigher

β-Nicotinamide Adenine Dinucleotide (NAD+)

NATCO launches Rivaroxaban¸ anticoagulant medication in India

expresspharmaDecember 18, 2020

Tag: NATCO , India , Rivaroxaban

Favorites

Natco Pharma announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under the brand name of Xarelto, in the Indian market.

“After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (novel oral anti-coagulant) is in line with our company’s mission of affordable medicines accessible to all,” informed a company release.

NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of Rs 14.0 per tablet.

Previous:Chlorhexidine mouthwash can kill novel coronavirus: Study

Next:Novartis to acquire Cadent Therapeutics for $770 mn

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

NATCO launches Rivaroxaban¸ anticoagulant medication in India | Pharmasources.com

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.

NATCO launches Rivaroxaban¸ anticoagulant medication in India

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may like
More>>

NATCO launches Rivaroxaban¸ anticoagulant medication in India

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may likeMore>>

You may like
More>>